Evercore ISI raises Church & Dwight stock price target on detergent strength

Evercore ISI raised its price target on Church & Dwight to $105 from $103 while keeping an In Line rating, citing stronger relative positioning, detergent trade-down benefits, and 60% hedging that limits commodity cost pressure to $25 million-$30 million. The company also reported Q1 2026 adjusted EPS of $0.95 versus $0.93 expected and revenue of $1.47 billion versus $1.46 billion consensus, indicating a modest earnings beat. Portfolio restructuring and portfolio mix improvements are supporting reinvestment into higher-return brands like Arm & Hammer and TheraBreath.

Analysis

CHD is being rewarded less for a single-quarter beat than for demonstrating that its category mix has become structurally more defensive than peers. The key second-order effect is that trade-down in detergents is not just shifting share within household staples; it is concentrating wallet share toward operators with the cleanest shelf productivity and the least promotional dependency. That tends to create a self-reinforcing loop: better display quality drives velocity, which supports retailer confidence, which in turn reduces the need to discount.

The market may still be underappreciating how much of CHD’s earnings resilience comes from lower downside elasticity, not just hedging. A commodity spike that is absorbable via productivity is valuable because it preserves management’s option to reinvest rather than defend margins, and that typically compounds over 4-6 quarters. By contrast, PG’s heavier promotional intensity makes it more exposed to any consumer pullback: if shoppers keep trading down, the burden of maintaining share increasingly falls on gross-to-net, which is a slower and more value-destructive response.

The contrarian risk is that the current optimism is already pricing in a “safe haven staples” premium just as the easy share gains may be maturing. If commodity inflation stays contained and consumer demand stabilizes, the relative advantage narrows and CHD’s outperformance could compress back toward execution-only alpha. The bigger tell over the next 1-2 quarters is whether the company can continue converting innovation into distribution gains without needing incremental promotion; if that stalls, the multiple support is vulnerable.

Key Decisions for Investors

• Long CHD vs short PG for the next 3-6 months: prefer the company with lower promotional drag and higher reinvestment flexibility; target a 5-8% relative move if trade-down persists.
• Buy CHD on any 2-3% pullback over the next 2 weeks; use a tight stop if the market starts pricing a retreat in shelf-space or a reset in detergent pricing power.